Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
J Intensive Care Med ; 32(4): 264-272, 2017 May.
Artículo en Inglés | MEDLINE | ID: mdl-26130580

RESUMEN

PURPOSE: To use the 2010 to 2011 data collected by structured chart review to provide a detailed up-to-date description of the epidemiology and microbiology of the sepsis syndromes. METHODS: Prospective observational study conducted at a university-affiliated urban teaching hospital and level-1 trauma and burn center. All adult patients who triggered a Code Sepsis in the emergency department (ED) between January 2010 and December 2011 were included. RESULTS: One hundred eighty four patients presented with a verified sepsis syndrome and triggered a Code Sepsis in the ED during the studied time period. The mean hospital and intensive care unit length of stays (LOSs) were 15.4 (interquartile range [IQR] = 14) and 6.7 (IQR = 5) days, respectively. The total inpatient mortality was 19% (n = 35). Patients with an unspecified source of infection and those without an isolated pathogen had the highest inpatient mortality, 42.1% (n = 8) and 23.3% (n = 10), respectively. CONCLUSION: Hospital mortality and hospital LOS of sepsis are similar to those reported in other observational studies. Our study confirms a decline in the mortality of sepsis predicted by earlier longitudinal studies and should prompt a resurgence of epidemiological research of the sepsis syndromes in the United States.


Asunto(s)
Antibacterianos/uso terapéutico , Unidades de Quemados , Hospitales de Enseñanza , Sepsis/terapia , Centros Traumatológicos , Adulto , Femenino , Mortalidad Hospitalaria , Humanos , Unidades de Cuidados Intensivos , Tiempo de Internación/estadística & datos numéricos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Sepsis/microbiología , Sepsis/mortalidad , Índice de Severidad de la Enfermedad , Síndrome , Washingtón/epidemiología
2.
Antimicrob Agents Chemother ; 52(11): 3909-14, 2008 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-18765688

RESUMEN

The objective of this study was to investigate the trends and patterns of resistance in beta-lactamase-producing members of the family Enterobacteriaceae in a children's hospital over a 9-year period (1999 to 2007). Clinically significant isolates of the Enterobacteriaceae were screened for patterns of broad-spectrum resistance to beta-lactams. The strains likely to be resistant were subsequently confirmed by an inhibitor-based disc test. The plasmid-mediated resistance determinants in these isolates were identified by PCR and by in vitro transformation, which successfully reproduced the AmpC phenotype unrestricted by the species of the host organisms. Among 8,048 Enterobacteriaceae isolates belonging to the four chromosomal ampC-negative or -nonfunctional genera, 86 (1.07%) isolates (56 Escherichia coli isolates, 22 Klebsiella species isolates, 1 Proteus mirabilis isolate, and 7 Salmonella species isolates) exhibited broad-spectrum beta-lactam resistance patterns. These organisms collectively produced three classes of beta-lactamases, including class A extended-spectrum beta-lactamases (n = 47), class C or AmpC beta-lactamases (n = 36, including 4 isolates that produced both class A and class C enzymes), and class A or B carbapenem-hydrolyzing beta-lactamases (n = 3). The proportion increased from 0.46% during the first 3 years to 1.84% during the last 3 years (relative risk [RR], 4.04; 95% confidence interval [CI], 2.28 to 7.42; P < 0.001). The increase was mainly due to the emergence of a plasmid-mediated bla(CMY-2) beta-lactamase, the incidence of which increased from 0.11% during the first 3 years to 0.96% during the last 3 years (RR, 9.11; 95% CI, 2.76 to 30.1; P = 0.001). Class A-type resistance increased slightly during the study period, from 0.35% during the first 3 years to 0.85% during the last 3 years (RR, 2.42; 95% CI, 1.15 to 5.07; P = 0.02). A Proteus mirabilis strain was documented to possess a novel bla(DHA) determinant. Of special concern, three carbapenemase-producing isolates were identified between 2003 and 2006. The infections caused by resistant isolates of the Enterobacteriaceae mainly affected hospitalized patients with underlying conditions; however, 19 (22%) episodes were of community onset in otherwise well children. The rate of resistance to broad-spectrum beta-lactams among isolates of the Enterobacteriaceae is increasing in children in both hospital- and community-acquired settings, and the resistance is driven largely by plasmid-mediated AmpC beta-lactamases. These data have important implications for empirical antimicrobial strategies targeting serious pediatric infections. Further study of this problem is warranted.


Asunto(s)
Infecciones por Enterobacteriaceae/tratamiento farmacológico , Infecciones por Enterobacteriaceae/microbiología , Enterobacteriaceae/efectos de los fármacos , Resistencia betalactámica , Adolescente , Adulto , Secuencia de Bases , Niño , Preescolar , Infecciones Comunitarias Adquiridas/tratamiento farmacológico , Infecciones Comunitarias Adquiridas/epidemiología , Infecciones Comunitarias Adquiridas/microbiología , Cartilla de ADN/genética , ADN Bacteriano/genética , Enterobacteriaceae/enzimología , Enterobacteriaceae/genética , Enterobacteriaceae/aislamiento & purificación , Infecciones por Enterobacteriaceae/epidemiología , Femenino , Genes Bacterianos , Hospitales Pediátricos , Humanos , Lactante , Recién Nacido , Masculino , Factores de Tiempo , Washingtón/epidemiología , Adulto Joven , Resistencia betalactámica/genética , beta-Lactamasas/genética
3.
Int J STD AIDS ; 29(13): 1354-1358, 2018 11.
Artículo en Inglés | MEDLINE | ID: mdl-30114998

RESUMEN

We report a case of reactive hemophagocytic syndrome (RHS) in the setting of acute human immunodeficiency virus type 1 infection (AHI). In addition, we review 11 previously reported cases of RHS precipitated by AHI and discuss strategies in the diagnosis and management of these overlapping clinical entities.


Asunto(s)
Infecciones por VIH/diagnóstico , VIH-1/inmunología , Histiocitosis/diagnóstico , Linfohistiocitosis Hemofagocítica/diagnóstico , Corticoesteroides/uso terapéutico , Adulto , Antirretrovirales/uso terapéutico , Etopósido/uso terapéutico , Exantema/etiología , Infecciones por VIH/tratamiento farmacológico , Histiocitosis/tratamiento farmacológico , Humanos , Inyecciones Espinales , Linfohistiocitosis Hemofagocítica/tratamiento farmacológico , Masculino , Metotrexato/uso terapéutico , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA